Your browser doesn't support javascript.
loading
Single-cell multi-omics analysis of COVID-19 patients with pre-existing autoimmune diseases shows aberrant immune responses to infection.
Barmada, Anis; Handfield, Louis-François; Godoy-Tena, Gerard; de la Calle-Fabregat, Carlos; Ciudad, Laura; Arutyunyan, Anna; Andrés-León, Eduardo; Hoo, Regina; Porter, Tarryn; Oszlanczi, Agnes; Richardson, Laura; Calero-Nieto, Fernando J; Wilson, Nicola K; Marchese, Domenica; Sancho-Serra, Carmen; Carrillo, Jorge; Presas-Rodríguez, Silvia; Ramo-Tello, Cristina; Ruiz-Sanmartin, Adolfo; Ferrer, Ricard; Ruiz-Rodriguez, Juan Carlos; Martínez-Gallo, Mónica; Munera-Campos, Mónica; Carrascosa, Jose Manuel; Göttgens, Berthold; Heyn, Holger; Prigmore, Elena; Casafont-Solé, Ivette; Solanich, Xavier; Sánchez-Cerrillo, Ildefonso; González-Álvaro, Isidoro; Raimondo, Maria Gabriella; Ramming, Andreas; Martin, Javier; Martínez-Cáceres, Eva; Ballestar, Esteban; Vento-Tormo, Roser; Rodríguez-Ubreva, Javier.
Affiliation
  • Barmada A; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
  • Handfield LF; Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom.
  • Godoy-Tena G; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
  • de la Calle-Fabregat C; Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona, Spain.
  • Ciudad L; Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona, Spain.
  • Arutyunyan A; Epigenetics and Immune Disease Group, Josep Carreras Research Institute (IJC), Barcelona, Spain.
  • Andrés-León E; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
  • Hoo R; Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), Granada, Spain.
  • Porter T; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
  • Oszlanczi A; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
  • Richardson L; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
  • Calero-Nieto FJ; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
  • Wilson NK; Department of Haematology and Wellcome & MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
  • Marchese D; Department of Haematology and Wellcome & MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
  • Sancho-Serra C; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Carrillo J; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
  • Presas-Rodríguez S; IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Ramo-Tello C; MS Unit, Department of Neurology, Germans Trias i Pujol University Hospital, Barcelona, Spain.
  • Ruiz-Sanmartin A; MS Unit, Department of Neurology, Germans Trias i Pujol University Hospital, Barcelona, Spain.
  • Ferrer R; Department of Intensive Care, Hospital Universitari Vall d'Hebron, Shock, Organ Dysfunction and Resuscitation Research Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
  • Ruiz-Rodriguez JC; Department of Intensive Care, Hospital Universitari Vall d'Hebron, Shock, Organ Dysfunction and Resuscitation Research Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
  • Martínez-Gallo M; Department of Intensive Care, Hospital Universitari Vall d'Hebron, Shock, Organ Dysfunction and Resuscitation Research Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
  • Munera-Campos M; Division of Immunology, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
  • Carrascosa JM; Dermatology Service, Germans Trias i Pujol University Hospital, LCMN, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.
  • Göttgens B; Dermatology Service, Germans Trias i Pujol University Hospital, LCMN, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.
  • Heyn H; Department of Haematology and Wellcome & MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
  • Prigmore E; CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Casafont-Solé I; Universitat Pompeu Fabra (UPF), Barcelona, Spain.
  • Solanich X; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.
  • Sánchez-Cerrillo I; Department of Rheumatology, Germans Trias i Pujol University Hospital, LCMN, Germans Trias i Pujol Research Institute (IGTP), Barcelona, Spain.
  • González-Álvaro I; Department of Infectious Diseases, Germans Trias i Pujol University Hospital, Barcelona, Spain.
  • Raimondo MG; Department of Internal Medicine, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Ramming A; Department of Immunology, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain.
  • Martin J; Rheumatology Service, Hospital Universitario La Princesa, IIS-IP, Madrid, Spain.
  • Martínez-Cáceres E; Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
  • Ballestar E; Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
  • Vento-Tormo R; Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.
  • Rodríguez-Ubreva J; Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Eur J Immunol ; 54(1): e2350633, 2024 Jan.
Article de En | MEDLINE | ID: mdl-37799110
ABSTRACT
In COVID-19, hyperinflammatory and dysregulated immune responses contribute to severity. Patients with pre-existing autoimmune conditions can therefore be at increased risk of severe COVID-19 and/or associated sequelae, yet SARS-CoV-2 infection in this group has been little studied. Here, we performed single-cell analysis of peripheral blood mononuclear cells from patients with three major autoimmune diseases (rheumatoid arthritis, psoriasis, or multiple sclerosis) during SARS-CoV-2 infection. We observed compositional differences between the autoimmune disease groups coupled with altered patterns of gene expression, transcription factor activity, and cell-cell communication that substantially shape the immune response under SARS-CoV-2 infection. While enrichment of HLA-DRlow CD14+ monocytes was observed in all three autoimmune disease groups, type-I interferon signaling as well as inflammatory T cell and monocyte responses varied widely between the three groups of patients. Our results reveal disturbed immune responses to SARS-CoV-2 in patients with pre-existing autoimmunity, highlighting important considerations for disease treatment and follow-up.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladies auto-immunes / COVID-19 Limites: Humans Langue: En Journal: Eur J Immunol Année: 2024 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladies auto-immunes / COVID-19 Limites: Humans Langue: En Journal: Eur J Immunol Année: 2024 Type de document: Article Pays d'affiliation: Royaume-Uni
...